Table of Contents
Chapter 1 Report Scope and Objectives
1.1 Market Segmentation & Scope
1.2 Regional Scope
1.2.1 Estimates And Forecast Timeline
1.3 Objectives
1.3.1 Objective – 1
1.3.2 Objective – 2
1.3.3 Objective – 3
Chapter 2 Methodology
2.1 Research Methodology
2.2 Information Procurement
2.2.1 Purchased Database
2.2.2 Gvr’s Internal Database
2.2.3 Secondary Sources
2.2.4 Primary Research
2.3 Information Or Data Analysis
2.3.1 Data Analysis Models
2.4 Market Formulation & Validation
2.5 Model Details
2.5.1 Commodity Flow Analysis (Model 1)
2.5.2 Volume Price Analysis (Model 2)
2.6 List Of Secondary Sources
Chapter 3 Executive Summary
3.1 Market Outlook
3.2 Segment Outlook
3.2.1 Product Type
3.2.2 Cancer Type
3.2.3 End-Use
3.2.4 Region
3.3 Competitive Insights
3.4 Precision Oncology Market Outlook, 2020
Chapter 4 Market Variables, Trends & Scope
4.1 Market Lineage Outlook
4.1.1 Parent Market Outlook
4.1.2 Ancillary Market Outlook
4.2 Precision Oncology Market Dynamics
4.2.1 Market Driver Analysis
4.2.2 Market Restraint Analysis
4.3 Precision Oncology Market: Business Environment Analysis Tools
4.3.1 Porter’s Five Forces Analysis
4.3.2 Threat Of New Entrants
4.3.3 Bargaining Power Of Suppliers
4.3.4 Bargaining Power Of Buyers
4.3.5 Competitive Rivalry
4.3.6 Threat Of Substitutes
4.3.7 Pestel Analysis
4.3.7.1 Political & Legal Landscape
4.3.7.2 Economic Landscape
4.3.7.3 Technological Landscape
4.4 Penetration & Growth Prospect Mapping
4.5 Impact Of Covid-19 On Precision Oncology Market
Chapter 5 Precision Oncology Market: Product Type Analysis
5.1 Precision Oncology Market Share Analysis, 2020 & 2028
5.2 Precision Oncology Market: Segment Dashboard:
5.3 Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Product Type Segment
5.3.1 Diagnostics
5.3.1.1 Diagnostics Market, 2018 – 2030 (USD Million)
5.3.2 Therapeutics
5.3.2.1 Therapeutics Market, 2018 – 2030 (USD Million)
Chapter 6 Precision Oncology Market: Cancer Type Analysis
6.1 Precision Oncology Cancer Type Market Share Analysis, 2020 & 2028
6.2 Precision Oncology Cancer Type Market: Segment Dashboard:
6.3 Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The Cancer Type Segment
6.3.1 Breast Cancer
6.3.1.1 Breast Cancer Market, 2018 – 2030 (USD Million)
6.3.2 Colorectal Cancer
6.3.2.1 Colorectal Cancer Market, 2018 – 2030 (USD Million)
6.3.3 Cervical Cancer
6.3.4 Cervical Cancer Market, 2018 – 2030 (USD Million)
6.3.5 Prostate Cancer
6.3.5.1 Prostate Cancer Market, 2018 – 2030 (USD Million)
6.3.6 Lung Cancer
6.3.6.1 Lung Cancer Market, 2018 – 2030 (USD Million)
6.3.7 Others Cancer
6.3.7.1 Others Cancer Market, 2018 – 2030 (USD Million)
Chapter 7 Precision Oncology Market: End-Use Analysis
7.1 Precision Oncology End-Use Market Share Analysis, 2020 & 2028
7.2 Precision Oncology End-Use Market: Segment Dashboard:
7.3 Market Size & Forecasts And Trend Analyses, 2018 To 2030 For The End-Use Segment
7.3.1 Hospitals & Diagnostic Laboratories
7.3.2 Hospitals & Diagnostic Laboratories Market, 2018 – 2030 (USD Million)
7.3.3 Pharmaceutical & Biotechnology Companies
7.3.3.1 Pharmaceutical & Biotechnology Companies Market, 2018 – 2030 (USD Million)
7.3.4 Healthcare Data Companies
7.3.5 Healthcare Data Companies Market, 2018 – 2030 (USD Million)
Chapter 8 Precision Oncology Market: Regional Analysis
8.1 Precision Oncology Regional Market Share Analysis, 2020 & 2028
8.2 Regional Market Snapshot
8.3 North America
8.3.1 North America Precision Oncology Market, 2018 – 2030 (USD Million)
8.3.2 U.S.
8.3.2.1 U.S. Precision Oncology Market, 2018 – 2030 (USD Million)
8.3.3 Canada
8.3.3.1 Canada Precision Oncology Market, 2018 – 2030 (USD Million)
8.4 Europe
8.4.1 Europe Precision Oncology Market, 2018 – 2030 (USD Million)
8.4.2 U.K.
8.4.2.1 U.K. Precision Oncology Market, 2018 – 2030 (USD Million)
8.4.3 Germany
8.4.3.1 Germany Precision Oncology Market, 2018 – 2030 (USD Million)
8.4.4 France
8.4.4.1 France Precision Oncology Market, 2018 – 2030 (USD MILLION)
8.4.5 Italy
8.4.5.1 Italy Precision Oncology Market, 2018 – 2030 (USD Million)
8.4.6 Spain
8.4.6.1 Spain Precision Oncology Market, 2018 – 2030 (USD Million)
8.4.7 Denmark
8.4.8 Denmark Precision Oncology Market, 2018 – 2030 (USD Million)
8.4.9 Sweden
8.4.10 Sweden Precision Oncology Market, 2018 – 2030 (USD Million)
8.4.11 Norway
8.4.12 Norway Precision Oncology Market, 2018 – 2030 (USD Million)
8.5 Asia Pacific
8.5.1 Asia Pacific Precision Oncology Market, 2018 – 2030 (USD Million)
8.5.2 Japan
8.5.2.1 Japan Precision Oncology Market, 2018 – 2030 (USD Million)
8.5.3 China
8.5.3.1 China Precision Oncology Market, 2018 – 2030 (USD Million)
8.5.4 India
8.5.4.1 India Precision Oncology Market, 2018 – 2030 (USD Million)
8.5.5 Australia
8.5.5.1 Australia Precision Oncology Market, 2018 – 2030 (USD Million)
8.5.6 Thailand
8.5.7 Thailand Precision Oncology Market, 2018 – 2030 (USD Million)
8.5.8 South Korea
8.5.8.1 South Korea Precision Oncology Market, 2018 – 2030 (USD Million)
8.6 Latin America
8.6.1 Latin America Precision Oncology Market, 2018 – 2030 (USD Million)
8.6.2 Brazil
8.6.2.1 Brazil Precision Oncology Market, 2018 – 2030 (USD Million)
8.6.3 Mexico
8.6.3.1 Mexico Precision Oncology Market, 2018 – 2030 (USD Million)
8.6.4 Argentina
8.6.4.1 Argentina Precision Oncology Market, 2018 – 2030 (USD Million)
8.7 Middle East And Africa (Mea)
8.7.1 Mea Precision Oncology Market, 2018 – 2030 (USD Million)
8.7.2 South Africa
8.7.2.1 South Africa Precision Oncology Market, 2018 – 2030 (USD Million)
8.7.3 Saudi Arabia
8.7.3.1 Saudi Arabia Precision Oncology Market, 2018 – 2030 (USD Million)
8.7.4 UAE
8.7.4.1 UAE Precision Oncology Market, 2018 – 2030 (USD Million)
8.7.5 Kuwait
8.7.6 Kuwait Precision Oncology Market, 2018 – 2030 (USD Million)
Chapter 9 Competitive Analysis
9.1 Recent Developments & Impact Analysis, By Key Market Participants
9.2 Company Profiles
9.2.1 THERMO FISHER SCIENTIFIC INC.
9.2.1.1 Company overview
9.2.1.2 Financial performance
9.2.1.3 Product Benchmarking
9.2.1.4 Strategic initiatives
9.2.2 INVITAE CORPORATION
9.2.2.1 Company overview
9.2.2.2 Product Benchmarking
9.2.2.3 Strategic initiatives
9.2.3 QIAGEN N.V.
9.2.3.1 Company overview
9.2.3.2 Product Benchmarking
9.2.3.3 Strategic initiatives
9.2.4 ILLUMINA, INC.
9.2.4.1 Company overview
9.2.4.2 Product Benchmarking
9.2.4.3 Strategic initiatives
9.2.5 LABORATORY CORPORATION OF AMERICA HOLDING
9.2.5.1 Company overview
9.2.5.2 Product Benchmarking
9.2.5.3 Strategic initiatives
9.2.6 EXACT SCIENCES CORPORATION
9.2.6.1 Company overview
9.2.6.2 Product Benchmarking
9.2.6.3 Strategic initiatives
9.2.7 RAIN ONCOLOGY INC.
9.2.7.1 Company overview
9.2.7.2 Product Benchmarking
9.2.7.3 Strategic initiatives
9.2.8 STRATA ONCOLOGY, INC.
9.2.8.1 Company overview
9.2.8.2 Product Benchmarking
9.2.8.3 Strategic initiatives
9.2.9 XILIS, INC.
9.2.9.1 Company overview
9.2.9.2 Product Benchmarking
9.2.9.3 Strategic initiatives
9.2.10 VARIANTYX, INC.
9.2.10.1 Company overview
9.2.10.2 Product Benchmarking
9.2.10.3 Strategic initiatives
9.2.11 BIOSERVE
9.2.11.1 Company overview
9.2.11.2 Product Benchmarking
9.2.11.3 Strategic initiatives
9.2.12 RELAY THERAPEUTICS
9.2.12.1 Company overview
9.2.12.2 Product Benchmarking
9.2.12.3 Strategic initiatives
9.2.13 ACRIVON THERAPEUTICS
9.2.13.1 Company overview
9.2.13.2 Product Benchmarking
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/